In addition, to further explore the predictive value of MOXD1 regarding the response to immunotherapy in bladder cancer patients, we utilized the Comprehensive Analysis on Multi-Omics of Immunotherapy in Pan-cancer (CAMOIP) database to analyze the immune characteristics of the patients in the groups with high and low expression of MOXD1. This evidence concerns the gene MOXD1 and urinary bladder cancer.